Acetaminophen-Ibuprofen Composition With Micronized Ibuprofen Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NSAID formulations do not achieve optimal early and prolonged pain relief due to suboptimal pharmacokinetics, particularly with ibuprofen, which limits the rapid absorption and maximum plasma concentration, necessitating higher doses for effective analgesia.
Innovation Solution
A solid oral unit dosage form comprising acetaminophen and ibuprofen with specific particle size distribution, prepared by jet milling, to enhance in vitro dissolution rates and achieve higher maximum plasma concentration of ibuprofen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If ibuprofen particle size is reduced to below 1000 nm to achieve faster absorption, then maximum plasma concentration and analgesia onset are improved, but manufacturing complexity and processing difficulty increase
Solution Approach 1:
The patent optimizes ibuprofen particle size to a specific range (D10: 1-3 μm, D50: 2-8 μm, D90: 4-16 μm) rather than reducing it to below 1000 nm. This parameter optimization achieves rapid dissolution (80% or more in 15 minutes or less) and improved absorption while avoiding the manufacturing complexity associated with nanoscale particle production. The jet milling process parameters are specifically controlled to achieve this optimal particle size distribution.
2Quantity of substance
If ibuprofen dose is increased to achieve better pain relief, then analgesia efficacy is improved, but risk of side effects and gastrointestinal irritation increases
Solution Approach 1:
The patent changes the particle size parameter of ibuprofen to achieve rapid dissolution and absorption, enabling effective analgesia at a lower dose (97.5 mg or 150 mg). The optimized particle size distribution (D10: 1-3 μm, D50: 2-8 μm, D90: 4-16 μm) ensures that the smaller amount of ibuprofen is efficiently absorbed, providing pain relief comparable to or better than higher doses while reducing gastrointestinal side effects.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation containing ibuprofen, acetaminophen, and various excipients (binders, disintegrants, lubricants). This composite approach allows the ibuprofen to work synergistically with acetaminophen, enabling effective pain relief at lower ibuprofen doses and reducing the need for high single doses that cause gastrointestinal irritation.
3Ease of manufacture
If ibuprofen particle size is increased to simplify manufacturing, then processing ease is improved, but dissolution rate and maximum plasma concentration decrease
Solution Approach 1:
The patent identifies and optimizes specific particle size parameters (D10: 1-3 μm, D50: 2-8 μm, D90: 4-16 μm) that represent the optimal balance between manufacturing ease and dissolution rate. Jet milling is used to achieve this specific particle size distribution, which is coarse enough to be manufactured easily but fine enough to dissolve rapidly (80% or more in 15 minutes or less), achieving both manufacturing simplicity and rapid absorption.
4Device complexity
If standard ibuprofen formulation is used to maintain formulation simplicity, then formulation complexity is reduced, but pain relief duration and efficacy are insufficient
Solution Approach 1:
The patent develops a composite formulation containing both ibuprofen and acetaminophen in specific ratios. The ibuprofen component (with optimized particle size) provides rapid onset and prolonged pain relief, while acetaminophen provides complementary analgesic effects. This composite approach extends the duration of pain relief beyond what either drug could achieve alone, without significantly increasing formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation results in significantly higher Cmax for ibuprofen, providing earlier and longer-lasting analgesia, reducing the need for additional analgesics and improving pain relief efficacy.
Implementation Method 1
the dosage form has been prepared by jet milling a composition comprising 21-23% wt/wt ibuprofen and 73-75% wt/wt acetaminophen
Data Source
AI summary
Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 μm, are described.